Gene therapy in neuromuscular disorders.

Area of Science:

• Molecular Biology
• Genetics
• Neurology

Background:

• Monogenic neuromuscular disorders represent a significant unmet medical need.
• Gene therapy presents a promising therapeutic strategy for these conditions.
• Viral vectors are key delivery systems for gene therapy interventions.

Purpose of the Study:

• To review viral vectors and their mechanisms in gene therapy.
• To discuss clinical trials supporting gene therapy for Spinal Muscular Atrophy (SMA).
• To explore gene replacement therapy for other neuromuscular diseases.

Main Methods:

• Review of existing literature on viral vectors for gene therapy.
• Analysis of clinical trial data for approved SMA gene therapy (AVXS-101).
• Examination of gene replacement strategies for neuromuscular disorders.

Main Results:

• Viral vectors enable therapeutic transgene delivery to correct genetic defects.
• AAV9-based gene therapy (AVXS-101) is an approved treatment for SMA.
• Gene replacement therapy shows potential for various monogenic neuromuscular diseases.

Conclusions:

• Gene therapy, particularly using viral vectors, is a viable treatment modality for monogenic neuromuscular disorders.
• The success in SMA validates the potential of gene replacement strategies.
• Further research into gene therapy holds promise for a broader range of neuromuscular conditions.